



5 May 2020

## **ASX Announcement**

### **Penthrox approved in The Netherlands and Bosnia & Herzegovina.**

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in The Netherlands and Bosnia & Herzegovina. The Marketing Authorisation issued by the Medicines Evaluation Board of the Netherlands and the Agency for Medicinal Products and Medical Devices of Bosnia & Herzegovina is for Penthrox® to be used for Emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

The approval in the Netherlands is part of a set of four countries, including Greece, Hungary, and Malta.

Both the European Decentralised Procedure and the National phase is complete in The Netherlands. Penthrox has not achieved government reimbursement yet, however sales can be made to the private market, immediately.

Whilst the European Decentralised Procedure is complete for Greece, Malta and Hungary the next step to commence sales of Penthrox in these markets is to complete the National Phase. The approvals are expected during the course of 2020.

After the National Phase is complete, then MVP can apply for government reimbursement for the cost of Penthrox (which will make Penthrox free for patients, much like a PBS listing in Australia). Concurrently sales can be made into the private market where patients themselves bear the cost of Penthrox.

The approval in Bosnia is part of a separate process outside of the EU. Penthrox has not achieved government reimbursement yet and so sales can only be made to the private market, immediately.

*Authorised for release by MVP Company Secretary, Mark Edwards.*

**Enquiries:**

David Williams  
Chairman  
Medical Developments International Ltd  
+61 (0) 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 (3) 9547 1888



### **About Pentrox**

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.